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Objective: To identify the molecular differences between the transient and permanent chondrocyte
phenotype in osteophytic and articular cartilage.
Methods: Total RNA was isolated from the cartilaginous layer of osteophytes and from intact articular
cartilage from knee joints of 15 adult human donors and subjected to cDNA microarray analysis. The
differential expression of relevant genes between these two cartilaginous tissueswas additionally validated
by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and by immunohistochemistry.
Results: Among 47,000 screened transcripts, 600 transcripts were differentially expressed between
osteophytic and articular chondrocytes. Osteophytic chondrocytes were characterized by increased
expression of genes involved in the endochondral ossiﬁcation process [bone gamma-carboxyglutamate
protein/osteocalcin (BGLAP), bone morphogenetic protein-8B (BMP8B), collagen type I, alpha 2
(COL1A2), sclerostin (SOST), growth arrest and DNA damage-induced gene 45ß (GADD45ß), runt-related
transcription factor 2 (RUNX2)], and genes encoding tissue remodeling enzymes [matrix metal-
lopeptidase (MMP)9, 13, hyaluronan synthase 1 (HAS1)]. Articular chondrocytes expressed increased
transcript levels of antagonists and inhibitors of the BMP- and Wnt-signaling pathways [Gremlin-1
(GREM1), frizzled-related protein (FRZB), WNT1 inducible signaling pathway protein-3 (WISP3)], as well
as factors that inhibit terminal chondrocyte differentiation and endochondral bone formation [para-
thyroid hormone-like hormone (PTHLH), sex-determining region Y-box 9 (SOX9), stanniocalcin-2 (STC2),
S100 calcium binding protein A1 (S100A1), S100 calcium binding protein B (S100B)].
Immunohistochemistry of tissue sections for GREM1 and BGLAP, the two most prominent differentially
expressed genes, conﬁrmed selective detection of GREM1 in articular chondrocytes and that of BGLAP in
osteophytic chondrocytes and bone.
Conclusions: Osteophytic and articular chondrocytes signiﬁcantly differ in their gene expression pattern.
In articular cartilage, a prominent expression of antagonists inhibiting the BMP- and Wnt-pathway may
serve to lock and stabilize the permanent chondrocyte phenotype and thus prevent their terminal
differentiation. In contrast, osteophytic chondrocytes express genes with roles in the endochondral
ossiﬁcation process, which may account for their transient phenotype.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The generation of phenotypically stable hyaline repair cartilage
is still a challenge for regenerative medicine. The aim of therapeutic
strategies is not conﬁned to the induction of chondrogenesis buto: K. Gelse, Department of
rlangen, Krankenhausstr. 12,
: 49-9131-8533300.
s Research Society International. Palso includes the perpetuation of a stable, permanent cellular
phenotype that is typical for articular chondrocytes. Unfortunately,
cartilage repair approaches that focus on the recruitment of bone
marrow stem cells are not only confronted with insufﬁcient
chondrogenesis but also with the problem of chondrocyte hyper-
trophy and inadvertent endochondral ossiﬁcation1e4. Thus, the
cellular differentiation programme within cartilage repair tissue
recapitulates cellular processes that are similar to the fetal growth
plate, fracture callus or forming osteophytes5,6. All these tissues
have in common that their cartilaginous tissue is only an inter-
mediate state toward bone formation and their cells only adoptublished by Elsevier Ltd. All rights reserved.
K. Gelse et al. / Osteoarthritis and Cartilage 20 (2012) 162e171 163a transient chondrocytic phenotype. In contrast, chondrocytes of
healthy articular cartilage are characterized by a postmitotic status
and retain their unique phenotype for a period of many decades. To
date, the mechanisms that stabilize the articular chondrocyte
phenotype have not been fully identiﬁed. We hypothesize upon
a distinction between transient and permanent chondrocytes, and
the aim of this study was to investigate the differences in their gene
expression proﬁle.
Since phenotypically instable transient cartilage repair tissue is
available only to a limited degree and characterized by a heteroge-
neous composition, we focussed on the cartilaginous cap of mature
osteophytes which can be considered a prototype for cartilage
repair tissue that arises in a more predictive and uniform pattern.
Osteophytic chondrocytes originate from mesenchymal stem or
precursor cells, undergo chondrogenic differentiation leading
to the formation of cartilaginous tissue, that is, however, prone
to be replaced by endochondral ossiﬁcation in the mature
osteophyte5,7e11. Therefore, osteophytic chondrocytes represent
awell-suited substrate to investigate the transcriptional differences
between transient chondrocytes and permanent chondrocytes
from articular cartilage.Materials and methods
Tissue samples and preparation
Human articular and osteophytic cartilage probes were obtained
as matched pairs from the same respective knee joints of 15 indi-
vidual patients [with a mean  standard deviation (SD) age of
68.2  6.7 years] undergoing total knee arthroplasty for osteoar-
thritis (OA) at the University Hospital Erlangen. The diagnosis of
primary OA was based on clinical and radiographic evaluations
according to standard criteria and patients with any secondary OA
or rheumatoid arthritis were excluded.
Articular cartilage was isolated from the dorsal part of the
femoral condyles with a macroscopically intact joint surface char-
acterized by an Outerbridge score of 0 or 1. Osteophytic cartilage
was isolated from the same respective joints from the cartilaginous
cap of the osteophyte outgrowths located at the edges of the
femoral condyles. Osteophytes were distinguished from the
marginal transition area of the joint surface by the existence of
a concave ridge toward the joint surface. In order to selectively
isolate the cartilaginous cap of the osteophyte and to exclude any
abrasion of bone trabeculae and calciﬁed tissue of the deepest
cartilaginous zone, only minimal forces were applied with a scalpel
by cutting tangentially to the surface to yield thin consecutive slices
of less than 1 mm thickness. Informed consent was obtained fromTable I
Primer/probe sets of target genes used for quantitative RT-PCR (TaqMan Gen Expression
Genes Gene expression ass
ACAN Hs00153936_m1
SOX9 Hs00165814_m1
RUNX2 Hs00231692_m1
COL1A2 Hs00164099_m1
COL10A1 Hs00166657_m1
PTHLH Hs00174969_m1
MMP13 Hs00233992_m1
FRZB Hs00173503_m1
Forward Rev
GREM1 GTGACGGAGCGCAAATACC CCT
BGLAP CGGTGCAGAGTCCAGCAAA AGC
GADD45ß ATTGACGAGGAGGAGGAGGA CGT
ß2M TGACTTTGTCACAGCCCAAGATA AATeach patient prior to surgery, and the institutional ethics
committee approved the study protocol.
Microarray
Total RNA was isolated from articular or osteophytic cartilage
tissue as described previously in detail11. The quality of isolated
RNA was assessed using the Agilent 2100 bioanalyzer (Agilent
Technologies, Santa Clara, CA), and the concentration was deter-
mined with a Spectrophotometer (ND 1000; NanoDrop Technolo-
gies, Rockland, DE). RNA preparations from a total of 15 different
donors were used. Three paired sets of RNA preparations of
articular and osteophytic cartilage each of ﬁve donors in equal
quantities were used for analysis. The appropriate pooling of RNA
samples had been shown to be statistically valid for microarray
experiments.51 Gene expression proﬁling was performed with the
Affymetrix Human Genome (HG) U133 Plus 2.0 Arrays (Affymetrix,
Santa Clara, CA) according to the manufacturer’s instructions. The
Genechip U133 Plus 2.0 is a comprehensive whole human genome
expression array with over 47,000 transcripts. Genes highly
expressed by articular and osteophytic chondrocytes were identi-
ﬁed by comparing gene expression levels between the two groups.
Quantitative reverse transcriptase polymerase chain reaction
(RT-PCR)
To conﬁrm the validity of the microarray, the individual RNA
preparations of 15 donors were additionally analyzed by real-time
RT-PCR using an ABI Prism 7900 sequence detection system
(Applied Biosystems, Foster City, CA) and Verso One-Step QRT-PCR
Rox Kit (Abgene, Hamburg, Germany) by quantifying the expres-
sion levels of functionally relevant genes including ACAN (aggre-
can), BGLAP (bone gamma-carboxyglutamate protein/osteocalcin),
COL1A2 (collagen type I, alpha 2), COL10A1 (collagen type X, alpha
1), FRZB (frizzled-related protein), GADD45ß (growth arrest and
DNA damage-induced gene 45ß), GREM1 (Gremlin-1), MMP13
(matrix metallopeptidase 13), PTHLH (parathyroid hormone-like
hormone), RUNX2 (runt-related transcription factor 2), SOX9
(sex-determining region Y-box 9), and ß2M (ß 2-microglobulin).
The relative quantiﬁcation of gene expressionwas performed using
the standard curvemethod. For each sample, the relative amount of
target mRNA was determined and normalized to that of ß2m
mRNA. Primer and probe sets are shown in Table I.
Immunohistological analysis
Osteochondral specimens from the boundary region of articular
cartilage and osteophyte were ﬁxed in 4% paraformaldehyde forAssays, Applied Biosystems)
ay ID Reference sequence
NM_013227
NM_000346
NM_004348
NM_000089
NM_000493
NM_002820
NM_002427
NM_001463
erse Probe
TCCTCGTGGATGGTCT AGACTGGTGCAAAACCCAGCCG
GCCTGGGTCTCTTCACT TGCAGCCTTTGTGTCCAAGCAGGAG
TGTCACAGCAGAAGGAC ATCGCCCTGCAAATCCACTTCACG
CCAAATGCGGCATCTTC TGATGCTGCTTACATGTCTCGATCCCA
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acetic acid (EDTA) for 3 months. After standard processing, the
samples were embedded in parafﬁn. Specimens were cut in serial
transverse 5 mm sections and stained with Toluidine blue and
Safranin-O/fast green for morphological assessment.
For immunohistochemical detection of GREM1 and BGLAP,
deparafﬁnized sections were pretreated either with 10 mM citrate
buffer (pH 6) at 90C for 20min, or with 0.2% hyaluronidase (Roche,
Mannheim, Germany) (pH 5.5) at 37C for 60 min, respectively,
followed by Protease XXIV (0.02mg/ml) (SigmaeAldrich, Hamburg,
Germany) for 60 min. The sections were then left to react overnight
at 4C either with rabbit anti-human GREM1 antibodies (AP6133a;
Abgent, San Diego, CA) diluted 1:50, or with monoclonal mouse
anti-human BGLAP antibodies (8H12; Acris, Herford, Germany)
diluted 1:10, respectively. Negative control sections for GREM1 and
BGLAP were incubated with isotype normal mouse IgG (Santa
Cruz). The sections were incubated with biotinylated anti-rabbit or
anti-mouse secondary antibodies (Dianova, Hamburg, Germany),
respectively. Bound antibodies were visualized by exposure to
a complex of streptavidin and biotinylated alkaline phosphatase
(Vectastain, ABC-AP, Vector Laboratories, Burlingame, CA, USA). The
sections were developed with fast red and counterstained with
hematoxylin.
Immunohistochemical detection of type I and type II collagen
was performed as described previously in detail12.
Statistical analysis
The microarray data of N ¼ 3 paired preparations were analyzed
with Partek Genomics Suite software (St. Louis, MO). Gene
expression between the two cartilaginous tissues was considered
to be signiﬁcant if the false discovery rates were less than 0.005 and
the fold-changes were three-fold or higher between the different
microarrays. Quantitative gene expression of paired individual
preparations from N ¼ 15 different donors was analyzed by
GraphPad InStat3 (La Jolla, CA) using a paired t-test with P < 0.05
considered signiﬁcant. All data are presented as mean with 95%
conﬁdence intervals (CIs) (lower, upper).
Results
Gene microarray analysis
Applying the comprehensive microarray analysis with 47,000
screened transcripts, 515 transcripts were signiﬁcantly higher
expressed (more than three-fold) in osteophytic chondrocytes, and
85 transcripts were signiﬁcantly higher expressed (more than
three-fold) in articular chondrocytes (P < 0.005) respectively.
Among those genes, 34 transcripts were characterized by differ-
ential expression that reached a high level of signiﬁcance with 31
transcripts being expressed more than 20-fold higher in osteo-
phytic chondrocytes, and three transcripts being expressed more
than 20-fold higher in articular chondrocytes (Fig. 1, Table II).
Genes signiﬁcantly higher expressed in osteophytic cartilage
Based on the functional clustering of the differentially expressed
genes, we detected several signaling factors with higher expression
in osteophytic cartilage which have a role in terminal chondrocyte
differentiation including bone morphogenetic protein-8B (BMP8B),
RUNX2, SOST (sclerostin), TWIST1 (twist homolog 1) and GADD45ß
(Table III). Quantitative RT-PCR of selected relevant genes
conﬁrmed the validity of the microarray analysis with signiﬁcantly
elevated transcript levels for RUNX2 (12.67-fold) and GADD45ß
(2.66-fold) in osteophytic cartilage (Fig. 2).Osteophytic chondrocytes were also characterized by a signiﬁ-
cantly greater expression of genes that encode molecules which are
involved in the endochondral ossiﬁcation process, including BGLAP,
COL1A2, and COL1A1 (collagen type I, alpha 1). Quantitative RT-PCR
conﬁrmed signiﬁcant upregulation of BGLAP (52.78-fold) and
COL1A2 (14.18-fold) in osteophytic cartilage (Fig. 2, Table III). The
striking differential expression of BGLAP was primarily a result of
its nearly absent expression in articular cartilage (0.56% of ß2M
levels), since the expression in osteophyte cartilage was only
moderate (29.7% of ß2M levels) (Fig. 2). Upregulation of COL10A1,
a marker gene for chondrocyte hypertrophy, did not reach the level
of signiﬁcance in specimen from osteophytes as detected by
quantitative RT-PCR (P ¼ 0.063).
Osteophytic chondrocytes exhibited a higher expression of
VCAN (versican), a proteoglycanwhich is ubiquitously expressed in
various tissues and not speciﬁc for hyaline cartilage (Table III).
Furthermore, osteophytic chondrocytes were characterized by
a signiﬁcantly higher expression of enzymes which mediate tissue
resorption and remodeling, including MMP9, MMP13, as well as
HAS1 (hyaluronan synthase 1). Quantitative RT-PCR conﬁrmed
a 12.8-fold upregulation of MMP13 in osteophytic cartilage (Fig. 2,
Table III).
Genes signiﬁcantly higher expressed in articular cartilage
Microarray analysis revealed that a number of genes which have
a role in chondrogenesis and maintenance of the cartilage matrix
had a signiﬁcantly higher expression in articular cartilage. Func-
tional clustering demonstrated upregulation of genes that encode
for factors involved in growth factor-signaling, including GREM1,
STC2 (stanniocalcin-2), WISP3 (WNT1 inducible signaling pathway
protein-3), S100B (S100 calcium binding protein B), S100A1 (S100
calcium binding protein A1), GDF5 (growth and differentiation
factor-5), FRZB, SOX9 and PTHLH (Tables II and IV). GREM1 was the
gene with the most prominent differential expression between
articular and osteophytic cartilage with a 24.77-fold upregulation
in articular cartilage (Fig. 2, Tables II and IV). In articular cartilage,
GREM1 transcript levels amounted to 76.5% of ß2M levels
(compared to 3.3% of ß2M levels in osteophytic cartilage). Quanti-
tative RT-PCR also conﬁrmed a 10.02-fold upregulation of FRZB in
articular cartilage. SOX9, a key transcription factor for chondro-
genesis and cartilage-speciﬁc genes, was moderately (2.59-fold),
yet signiﬁcantly (P ¼ 0.026) higher expressed in articular cartilage.
Quantitative RT-PCR could also demonstrate a signiﬁcantly (5.42-
fold) higher expression of PTHLH in articular cartilage.
The microarray analyses demonstrated signiﬁcantly greater
expression of the matrix molecules ACAN and SDC1 (syndecan 1) in
articular cartilage. A 11.30-fold higher expression of ACAN could be
detected in articular chondrocytes by quantitative RT-PCR (Fig. 2,
Table IV).
Furthermore, HS3ST3A1 (heparan sulfate 3-O-sulfotransferase
3A1) was found to be expressed signiﬁcantly higher in articular
cartilage (Fig. 2, Table IV).
Histological differences between osteophytic and articular cartilage
Immunohistological analysis of tissue sections revealed simi-
larities but also distinct differences between osteophytic and
articular cartilage isolated from osteoarthritic joints. While
articular cartilage is typically characterized by a homogeneous
proteoglycan-rich matrix indicated by strong Safranin-O- and
Toluidine blue-staining throughout all of its tissue layers, osteo-
phytic cartilage shows a stratiﬁed pattern [Fig. 3(A) and (B)]. In
contrast to articular cartilage, the superﬁcial half of the osteophytic
cartilage layer is characterized by less intense Safranin-O-staining
Fig. 1. Gene expression proﬁle by cDNA array-analysis. Heat map visualizing hierarchical clustering analysis based on the expression levels of genes that are differentially expressed
in osteophytic cartilage compared to articular cartilage. RNA preparations from N ¼ 15 different donors were pooled to yield N ¼ 3 paired sets of articular and osteophytic cartilage.
The genes with a differential expression greater than 20-fold are shown. P-value < 0.005. (Red ¼ higher expressed genes; blue ¼ lower expressed genes).
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ﬁbrocartilaginous tissue. Instead, the lower half of osteophytic
cartilage strongly stains for Safranin-O and Toluidine blue indi-
cating a high content of proteoglycans. This layer also strongly
stains for type II collagen (Col2) but is negative for Col1, which are
basically typical features of hyaline articular cartilage. Thus, gross
observation suggests similarities between this hyaline layer of
osteophytic cartilage and articular cartilage, however, higher
magniﬁcations reveal deﬁnite differences. Most obviously, the
deepest cell layer of osteophytic cartilage is characterized by large
hypertrophic chondrocytes [Fig. 3(C)] which are absent in intact
articular cartilage [Fig. 3(C)]. However, these hypertrophic chon-
drocytes are conﬁned to the very deepest cell layer of osteophytic
cartilage and not present in the overlying hyaline zone which
consists of chondrocytes characterized by a non-hypertrophic
phenotype [Fig. 3(C), middle zone]. Furthermore, in contrast to
articular cartilage, osteophyte cartilage lacks a tide mark and
a continuous plain subchondral bone plate, but exhibits a zone of
irregular bone trabeculae.
Immunohistochemical detection of GREM1 [Fig. 3(D)] and
BGLAP [Fig. 3(E)], the two most prominently differentially
expressed genes, conﬁrmed striking differences between osteo-
phytic and articular cartilage. Articular chondrocytes were char-
acterized by strong intracellular staining for GREM1 [arrows in
Fig. 3(D)]. However, in osteophytic cartilage, GREM1 could neither
be detected within the matrix, nor intracellularly within theosteophytic chondrocytes [open arrowheads in Fig. 3(D)]. GREM1
could be detected in the endothelial cell layer of invading bone
marrow structures, but not in the bone trabeculae of osteophytes or
the subchondral bone plate underneath articular cartilage.
BGLAP could immunohistochemically strongly be detected in
osseous tissue both in the forming bone trabeculae of the osteo-
phyte and the subchondral bone plate underneath the articular
cartilage. Interestingly, most osteophytic chondrocytes, even non-
hypertrophic chondrocytes within the middle zone, also showed
positive intracellular staining for BGLAP, whereas articular chon-
drocytes and hyaline articular cartilage matrix were completely
negative for BGLAP [Fig. 3(E)].
Discussion
This was the ﬁrst study to compare the genome-wide expres-
sion analysis of osteophytic and articular cartilage. Applying
microarray analysis, we could demonstrate signiﬁcant differences
between these two cartilaginous tissues. The fundamental differ-
ence is based on the fact that osteophytic chondrocytes adopt
a rather transient than permanent phenotype, which is underlined
by its tendency to recapitulate the chondrogenic differentiation
cascade cumulating in chondrocyte hypertrophy and endochon-
dral ossiﬁcation. Such phenotypic instability is also typical for
cartilage repair tissue that had been induced by bone marrow-
stimulating techniques, and although the cell origin may be
Table II
Differentially expressed genes in osteophytic cartilage (OC) and articular cartilage (AC) (change > 20-fold; P-value < 0.005)
GenBank accession
number
Gene symbol Gene title Fold-change
(OC vs AC)
P-value
206956_at BGLAP Bone gamma-carboxyglutamate (gla) protein 91.22 0.003
203936_s_at MMP9 Matrix metallopeptidase 9 65.53 0.001
204638_at ACP5 Acid phosphatase 5, tartrate resistant 47.38 0.001
200974_at ACTA2 Actin, alpha 2, smooth muscle, aorta 42.86 0.002
209301_at CA2 Carbonic anhydrase II 37.98 0.003
226237_at Col8a1 Collagen, type VIII, alpha 1 36.03 0.001
203548_s_at LPL Lipoprotein lipase 34.57 0.001
203666_at CXCL12 Chemokine (C-X-C motif) ligand 12 33.31 0.0003
203549_s_at LPL Lipoprotein lipase 32.90 0.002
202878_s_at CD93 CD93 molecule 32.29 0.001
208175_s_at DMP1 Dentin matrix acidic phosphoprotein 1 32.00 0.0004
204469_at PTPRZ1 Receptor-type tyrosine-protein phosphatase zeta 31.29 0.001
203980_at FABP4 Fatty acid binding protein 4, adipocyte 31.26 0.0003
235275_at BMP8B BMP8B 28.71 0.0001
223869_at SOST Sclerostin 26.76 0.004
202112_at VWF Von Willebrand factor 25.50 0.0004
229313_at ANO5 Anoctamin 5 24.18 0.0003
238066_at RBP7 Retinol binding protein 7, cellular 23.90 0.0001
213435_at SATB2 SATB homeobox 2 23.50 0.002
205624_at CPA3 Carboxypeptidase A3 (mast cell) 22.88 0.001
209555_s_at CD36 CD36 molecule (thrombospondin receptor) 22.88 0.0046
228766_at CD36 CD36 molecule (thrombospondin receptor) 22.66 0.0004
236858_s_at RUNX2 Runt-related transcription factor 2 22.46 0.0001
236858_s_at SUPT3H Transcription initiation protein SPT3 homolog 22.46 0.0001
208981_at PECAM1 Platelet/endothelial cell adhesion molecule 21.74 0.003
229218_at COL1A2 Collagen, type I, alpha 2 21.27 0.002
214677_x_at CYAT1 Cyclosporin A transporter 1 21.08 0.001
214677_x_at IGLV1-44 Immunoglobulin lambda variable 1-44 21.08 0.001
206488_s_at CD36 CD36 molecule (thrombospondin receptor) 20.96 0.0005
236859_at RUNX2 Runt-related transcription factor 2 20.84 0.0003
225975_at PCDH18 Protocadherin 18 20.15 0.001
209071_s_at RGS5 Regulator of G-protein signaling 5 20.09 0.004
214063_s_at TF Transferrin 21.95 0.001
218469_at GREM1 Gremlin-1 22.81 0.002
207016_s_at ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 24.85 0.0001
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a model system for endogenous cartilage repair tissue1,10. So far,
the molecular mechanisms, which distinguish between the tran-
sient and permanent chondrocyte phenotype, have not fully beenTable III
Selected genes with roles in chondrogenesis and osteogenesis with higher expression in
GenBank
accession
number
Gene
symbol
Gene title Fo
(O
Signaling factor/receptors
NM_001720 BMP8B BMP8B 28
NM_025237 SOST Sclerostin 26
NM_004348 RUNX2 Runt-related transcription
factor 2
20
NM_000474 TWIST1 Twist homolog 1 (Drosophila) 6
NM_015675 GADD45B Growth arrest and DNA
damage-inducible, beta
3
Matrix molecules
NM_199173 BGLAP Bone gamma-carboxyglutamate
(gla) protein (osteocalcin)
91
NM_000089 COL1A2 Collagen type I, alpha 2 21
NM_000088 COL1A1 Collagen, type I, alpha 1 12
NM_004385 VCAN Versican 8
NM_000493 COL10A1 Collagen, type X, alpha 1 4
Enzymes
NM_004994 MMP9 Matrix metallopeptidase 9
(gelatinase B)
65
NM_002427 MMP13 Matrix metallopeptidase 13
(collagenase 3)
16
NM_001523 HAS1 Hyaluronan synthase 1 7
* All P values were signiﬁcant (<0.005 for microarray analysis) or (<0.05 for quantitaidentiﬁed. This study further contributes to the knowledge of
the control of chondrogenesis and revealed striking differences in
the expression pattern between osteophytic and articular
cartilage.osteophytic cartilage (OC) in relation to articular cartilage (AC)
ld-change
C vs AC)
P-value* qRT-PCR
Fold-change (OC vs AC)
mean (95% CI)
P-value*
.71 0.0001
.76 0.004
.84 0.0003 12.67 (14.0e39.4) 0.012
.29 0.006
.61 0.225 2.66 (0.5e5.8) 0.004
.22 0.003 52.78 (16.2e89.4) 0.017
.27 0.002 14.18 (0.6e28.9) 0.040
.51 0.003
.12 0.002
.56 0.037 7.24 (18.933.4) 0.063
.53 0.001
.68 0.032 12.80 (1.8e27.4) 0.048
.75 0.004
tive RT-PCR), except for the P values for genes TWIST1 and Col10A1.
Fig. 2. Genes involved in chondrogenesis and endochondral ossiﬁcation that are
characterized by striking differential expression in osteophytic chondrocytes (OC) and
articular chondrocytes (AC). The values represent the mean and 95% CI (error bars) of
the fold-change in mRNA expression between osteophytic and articular chondrocytes
of N ¼ 15 different donors detected by quantitative RT-PCR.
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induced and supported by the action of BMPs,members of the TGFß
superfamily that are involved in morphogenesis, bone formation
and skeletal development5,13e15. Indeed, we could detect signiﬁ-
cantly greater expression of BMP8B in osteophytic chondrocytes. Its
high homology to the bone-inducing factor BMP7, and its functional
roles for embryonal cell differentiation and bone formation16,17,
underline its role for osteophyte formation.
Interestingly, the data of this study suggest a contrary pattern
for articular cartilage in which the action of BMPs seems sup-
pressed. Indeed, GREM1, a BMP-antagonist, was the gene which
expression was most prominently higher in articular chondrocytes
compared to osteophytic chondrocytes. Immunohistochemistry for
GREM1 conﬁrmed strong staining within articular chondrocytes
but absent staining in osteophytic chondrocytes. GREM1 binds and
blocks the action of BMP-2, -4 and-7, both on extra- and intracel-
lular levels18. Intracellular binding was shown to exert more potent
antagonistic effects19. In fact, we detected GREM1 predominantly
intracellularly rather than extracellularly within the matrix of
articular cartilage. During early embryogenic development, GREM1
is centrally involved in a self-regulatory feedback system that
controls limb formation and supports the maintenance of theTable IV
Selected genes with roles in chondrogenesis and osteogenesis with higher expression in
GenBank
accession
number
Gene
symbol
Gene title
Signaling factors/receptors
NM_013372 GREM1 Gremlin-1
NM_003714 STC2 Stanniocalcin-2
NM_003880 WISP3 WNT1 inducible signaling
pathway protein-3
NM_006272 S100B S100 calcium binding protein B
NM_006271 S100A1 S100 calcium binding protein A1
NM_000557 GDF5 Growth differentiation factor-5
NM_001463 FRZB Frizzled-related protein
NM_000346 SOX9 SRY (sex-determining region Y)-box 9
NM_002820 PTHLH Parathyroid hormone-like hormone
Matrix molecules
NM_001135 ACAN Aggrecan
NM_002997 SDC1 Syndecan 1
Enzymes
NM_006042 HS3ST3A1 Heparan sulfate (glucosamine)
3-O-sulfotransferase 3A1
* All P values were signiﬁcant (<0.005 for microarray analysis) or (<0.05 for quantitachondrocyte phenotype in early skeletal development20. In later
developmental stages, GREM1 plays a central role in epiphyseal
development. A recent genome wide microarray analysis identiﬁed
GREM1 to be the most prominently higher expressed gene in the
region of the epiphyses compared to the hypertrophic physeal zone
of developing bones of 7-day-old mice21. The authors concluded
that GREM1 helps to maintain the chondrocyte phenotype within
the epiphyses, while the action of BMPs propagates endochondral
ossiﬁcation in the physes. In another study, GREM1 was predomi-
nantly detected in the resting zone of the growth plate of new-born
rats, which may help to maintain the cells in a quiescent, non-
hypertrophic state22. In our study, we could conﬁrm the rele-
vance of GREM1 in adult human tissue. GREM1 was signiﬁcantly
higher expressed in human articular chondrocytes, a cell pop-
ulation that maintains its phenotype and resists terminal differ-
entiation, whereas GREM1 was not relevantly detected in
osteophytic chondrocytes. The levels of GREM1 in articular carti-
lage were shown to be even further increased in OA 23. The bio-
logical function of this phenomenon is still unclear, but may be
secondarily triggered by elevated BMP-2/-4 levels present in oste-
oarthritic joints23. Interestingly, other previous studies demon-
strated that overexpression of GREM1 inhibited BMP-induced
osteophyte formation14 and that elevated GREM1-levels were
measured in non-union fracture callus inwhich cartilaginous callus
failed to undergo ossiﬁcation24.
GREM1 may also have a role in other tissues such as endothelial
structures25. Immunohistochemically, we could also detect GREM1
in the endothelium of ingrowing vessels, however, we could not
detect GREM1 within bone trabeculae of osteophytes or the sub-
chondral bone plate underneath the articular cartilage.
In articular cartilage, the microarray analysis also revealed
a signiﬁcantly higher expression of STC2, WISP3, and FRZB. Similar
to GREM1, these factors also act as inhibitors and modulators
of growth factor-signaling. STC2 was shown to exhibit potent
growth-suppressive effects. Constitutive overexpression of STC2 in
mice resulted in pre- and postnatal growth restriction and delayed
intramembraneous and endochondral bone development26.
WISP3 was not only shown to inhibit BMP- and Wnt-signaling
but also to stabilize the chondrocyte phenotype by inhibiting
IGF-1-induced cellular maturation and hypertrophy27e29. FRZB
predominantly antagonizes the signaling of Wnt ligands and thusarticular cartilage (AC) in relation to osteophytic cartilage (OC)
Fold-change
(AC vs OC)
P-value* qRT-PCR P-value*
Fold-change (AC vs OC)
mean (95% CI)
22.81 0.002 24.77 (11.4e38.2) 0.011
8.34 0.001
7.12 0.002
6.00 0.001
4.50 0.003
4.45 0.005
3.78 0.004 10.02 (1.4e18.7) 0.030
2.25 0.066 2.59 (2.5e7.7) 0.026
1.39 0.216 5.42 (3.8e7.0) 0.016
4.23 0.003 11.30 (9.2e13.4) 0.003
3.82 0.001
16.50 0.003
tive RT-PCR).
Fig. 3. Immunohistochemical analysis of osteophytic and articular cartilage of the border zone of an osteoarthritic joint. (A): Overviews of the transition area of osteophyte and
articular cartilage. Insert with high magniﬁcation depicts the non-hypertrophic phenotype of articular chondrocytes in deep zones. (B): Higher magniﬁcations of osteophyte
cartilage demonstrate a superﬁcial Col1-positive ﬁbrocartilaginous layer, a deeper Col2-positive hyaline cartilage layer, and underlying osseous tissue. (C): High magniﬁcations
(Toluidine blue staining) of the lower half of osteophyte cartilage depict hypertrophic chondrocytes only in the deepest cell layer but not in the overlying middle zone. The deep
zone of articular cartilage is characterized by a clear tide mark without cellular hypertrophy within the overlying non-calciﬁed cartilage. (D): GREM1 immunohistochemistry shows
positive staining for endothelial structures (*) but negative staining for subchondral bone. Higher magniﬁcations demonstrate negative staining for osteophytic chondrocytes (open
arrowhead) but strong intracellular staining for articular chondrocytes (arrow). (E): BGLAP immunohistochemistry shows strong positive staining for subchondral bone. Osteophytic
chondrocytes are characterized by intracellular staining for osteocalcin, whereas articular chondrocytes are completely negative. (F): No non-speciﬁc staining was evident in
negative controls incubated with isotype normal mouse IgG. Bar ¼ 1 mm in A, B; Bars ¼ 50 mm in C, D, E, F. Safranin-OeFast green staining; Toluidine blue staining.
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bones, FRZB was prominently expressed within the epiphyses and
delays transformation to hypertrophy and endochondral
ossiﬁcation21,30.
S100A and S100B are factors that are abundantly present in
articular cartilage. Although their roles have not completely been
deﬁned yet, they were shown to inhibit terminal chondrocyte
differentiation and, thus, may stabilize the permanent chondrocyte
phenotype31. S100A and S100B are under the transcriptional
control of SOX9, which is the key transcription factor for cartilage-
speciﬁc genes32. The present study conﬁrmed signiﬁcant higher
expression of SOX9 in permanent articular cartilage compared to
transient osteophytic cartilage. SOX9 is known to inhibitchondrocyte hypertrophy and calciﬁcation, which is an effect that
may, at least in part, be mediated by transcriptional activation of
PTHLH33, which delays or inhibits terminal chondrocyte differen-
tiation and endochondral ossiﬁcation during skeletal development
and repair34,35. Thus, it was not surprising to ﬁnd PTHLH signiﬁ-
cantly higher expressed in permanent articular cartilage.
Articular cartilage is generally characterized by a low turnover
rate of cellular components and the collagen network, with the
exception of the high turnover rate of the proteoglycan content. The
inherent need tomaintain the integrity of the extracellular cartilage
matrix was reﬂected by high expression of ACAN and HS3ST3A1 in
articular chondrocytes. On the contrary, osteophytic cartilage is
characterized by a high expression of collagens including the types
K. Gelse et al. / Osteoarthritis and Cartilage 20 (2012) 162e171 169COL1A1 and COL1A2, which are characteristic of ﬁbrous tissue and
may primarily be ascribed to the superﬁcial ﬁbrocartilaginous zone.
It is important to clearly distinguish the transient chondrocyte
phenotype from the hypertrophic chondrocyte phenotype. While
transient chondrocytes display many features of articular chon-
drocytes such as production of a hyaline-like matrix, hypertrophic
chondrocytes are terminally differentiated cells in a pre-apoptotic
status and immediately prone to be replaced by osseous tissue.
Although, transient osteophytic cartilage ﬁnally underlies endo-
chondral ossiﬁcation, this process is prolongated in osteophytes.
Previous histochemical studies demonstrated a restriction of
positive COL10-staining to the very deepest cell layer of osteophyte
cartilage, while the overlying zones were negative for COL1010,36.
Since COL10 is a typical marker for chondrocyte hypertrophy and
terminal differentiation, such restricted staining pattern indicates
that most osteophytic chondrocytes have not attained the status of
hypertrophy yet. This is also conﬁrmed by gene expression anal-
yses of the present study with only marginal, but not signiﬁcant,
upregulation of COL10A1. Thus, the osteophytic specimen of this
study contained for the utmost part non-hypertrophic cells.
Nevertheless, their transient character was underlined by greater
expression of matrix metalloproteinases, including MMP9, and
MMP13, that are responsible for matrix remodeling and
resorption.
In osteophytic chondrocytes, BGLAP was the most striking
differentially expressed gene with a 91.22-fold higher expression.
Originally, this protein was deﬁned as an osteoblastic marker
protein and its expression in chondrocytes has not been published
so far. The positive intracellular staining of BGLAP even in non-
hypertrophic osteophytic chondrocytes may suggest an osteo-
genic fate of these cells. However, the relevance of BGLAP should be
interpreted with care since the expression levels in osteophytic
chondrocytes were only moderate and the dramatic difference
between the articular and osteophytic cartilage was primarily
a result of extremely low or even absent transcript levels of BGLAP
in articular chondrocytes (with less than 0.6% of the transcript
levels of ß2M). Nevertheless, the osteogenic fate of osteophytic
chondrocytes was underlined by signiﬁcantly elevated transcript
levels of RUNX2, an important transcription factor that induces
terminal chondrocyte differentiation, supports osteoblast differ-
entiation and is essential for bone formation and maturation37. In
osteophytic chondrocytes, we could also detect higher levels of
GADD45ß, a target of RUNX2. In recent studies, GADD45ß could be
detected in osteophytes and was also shown to be an essential
mediator of COL10A1 and MMP13 expression in hypertrophic
chondrocytes in the mouse embryo38,39.
Osteophytic chondrocytes were also characterized by higher
expression of TWIST1which is a transcription factor that plays both
positive and negative roles in the regulation of skeletal develop-
ment and differentiation of mesenchymal cells. As a target of the
canonical Wnt-signaling, TWIST1 was shown to suppress the
expression of chondrocyte-speciﬁc genes40 and promote osteoblast
differentiation and osteogenesis41.
Microarray analysis also revealed upregulation of SOST in
osteophytic chondrocytes. Originally, SOST was considered as
a product of osteocytes with inhibitory effects on osteoblasts and
formation of novel bone42. However, recent studies also detected
expression of SOST in hypertrophic chondrocytes of the growth
plate and chondrocytes of osteoarthritic cartilage43,44. Since SOST
expression was shown to be suppressed by PTH/PTHLH45, the
higher SOST expression in osteophytes may be a consequence of
decreased PTHLH levels. The functional role of SOST in osteophytic
cartilage has yet to be further investigated in detail, but it may exert
a modulatory role and decelerate the process of endochondral
ossiﬁcation42,43.On a transcriptional level, osteophytic cartilage shares similar-
ities with growth plate cartilage and fracture callus. Thus, a number
of genes that were signiﬁcantly greater expressed in osteophytic
cartilage, including BGLAP, RUNX2, GADD45B, MMP9, and MMP13,
are also expressed in the hypertrophic zone of growth plate
cartilage6,37,39,46e48 and involved in the process of fracture heal-
ing49. However, fracture callus and growth plate cartilage are
characterized by a considerably higher prevalence of hypertrophic
chondrocytes and a far more rapid endochondral ossiﬁcation
process than osteophyte tissue which develops over months or
years10,49. Thus, osteophytic cartilage contains transient, yet
predominantly non-hypertrophic chondrocytes, and is therefore
better suited for comparison with permanent articular cartilage.
Despite the careful harvesting technique of osteophytic cartilage
in the present study, some contamination with terminally differ-
entiated chondrocytes may not be completely excluded, however,
this drawback would exert rather an irrelevant statistical impact on
overall gene expression. Another limitation of this study is the
isolation of articular cartilage from osteoarthritic joints. However,
according to a previous comprehensive microarray analysis, artic-
ular cartilage of early degenerative osteoarthritic cartilage is char-
acterized by no or only marginal differences in its gene expression
proﬁle compared with healthy articular cartilage50. Thus, articular
chondrocytes from macroscopically intact cartilage, as used in this
study, should represent a valid population of normal articular
chondrocytes.
On a transcriptional level, the bradytrophic permanent articular
cartilage signiﬁcantly differs from osteophytic cartilage that is
characterized by cell proliferation and tissue remodeling including
anabolic and catabolic processes. Thus, articular chondrocytes are
characterized by a stable phenotype and their status of cellular
quiescence is reﬂected by the expression of a number of inhibitory
factors. The maintenance of the permanent articular cartilage may
not only be supported by the activity of pro-chondrogenic factors,
such as SOX9, but may also essentially depend on the activity of
antagonistic and inhibitory factors. In this respect, GREM1, WISP3
and FRZB, which modulate BMP- andWnt-signaling pathways may
lock the chondrocyte phenotype in articular cartilage and prevent
the terminal chondrocyte differentiation process. These data may
also provide novel concepts for regenerative strategies which may
not only focus on anabolic agents but which may also have to
consider the role of modulating antagonistic factors.
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